Head-To-Head Comparison: Incannex Healthcare (NASDAQ:IXHL) & Talphera (NASDAQ:TLPH)

Talphera (NASDAQ:TLPH) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Volatility & Risk

Talphera has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 6.97, suggesting that its share price is 597% more volatile than the S&P 500.

Earnings and Valuation

This table compares Talphera and Incannex Healthcare”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30,000.00	2,059.10	-$14.29 million	($0.27)	-4.41
Incannex Healthcare	$90,000.00	418.95	-$19.30 million	($1.69)	-1.86

Talphera has higher earnings, but lower revenue than Incannex Healthcare. Talphera is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Talphera and Incannex Healthcare, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1	1	2	0	2.25
Incannex Healthcare	1	0	1	0	2.00

Talphera currently has a consensus price target of $3.00, suggesting a potential upside of 152.10%. Incannex Healthcare has a consensus price target of $18.00, suggesting a potential upside of 471.43%. Given Incannex Healthcare’s higher possible upside, analysts clearly believe Incannex Healthcare is more favorable than Talphera.

Profitability

This table compares Talphera and Incannex Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Incannex Healthcare	N/A	-24.95%	-24.06%

Insider & Institutional Ownership

37.7% of Talphera shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Talphera beats Incannex Healthcare on 7 of the 13 factors compared between the two stocks.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

About Incannex Healthcare

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.